Form Type: 4

SEC EDGAR Link
Accession Number:0001140361-13-034588
Date:2013-08-27
Issuer: REGADO BIOSCIENCES INC (RGDO)
Original Submission Date:

Reporting Person:

WISNIEWSKI RAPHAEL
120 MOUNTAIN VIEW BOULEVARD
BASKING RIDGE, NJ 07920

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK, PAR VALUE $0.001 PER SHARE 2013-08-27 C 1,021,930 a $0.00 1,021,930 indirect f4
COMMON STOCK, PAR VALUE $0.001 PER SHARE 2013-08-27 C 169,633 a $0.00 1,191,563 indirect f4
COMMON STOCK, PAR VALUE $0.001 PER SHARE 2013-08-27 P 1,215,708 a $4.00 2,407,271 indirect f4
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 4.0 2023-08-27 deemed execution date A 17,964 (a) 2013-08-27 common stock, par value $0.001 per share 17,964 $4.00 17,964 direct
SERIES D PREFERRED STOCK 0.0 2013-08-27 deemed execution date C 17,066,243 (d) common stock, par value $0.001 per share 1,021,930 $0.00 0 indirect see footnote 4
SERIES E PREFERRED STOCK 0.0 2013-08-27 deemed execution date C 2,832,872 (d) common stock, par value $0.001 per share 169,633 $0.00 0 indirect see footnote 4
Footnotes
IDfootnote
f1 100% of the shares underlying the option will vest on the one-year anniversary of the date of grant.
f2 the shares of series d preferred stock had no expiration date and automatically converted upon the consummation of the initial public offering of regado biosciences, inc. (the "company") at a conversion ratio of 1 share of series d preferred stock to 0.05988024 shares of common stock, for no additional consideration.
f3 the shares of series e preferred stock had no expiration date and automatically converted upon the consummation of the company's initial public offering at a conversion ratio of 1 share of series e preferred stock to 0.05988024 shares of common stock, for no additional consideration.
f4 the reportable securities are directly held by biodiscovery 3, fcpr ("biodiscovery") and indirectly held by edmond de rothschild investment partners ("edmond de rothschild"), biodiscovery's management company. the reporting person is a partner at edmond de rothschild. the reporting person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of section 16 or for any other purpose.

Elevate your investments